Stifel Lifts Tandem Diabetes Price Target After Strong Quarter, Keeps Hold Rating
Stifel increased its 12-month price target for Tandem Diabetes Care to $22 from $20 while retaining a Hold rating, after a quarter that beat expectations on both U.S. and international revenue. The company’s revised go-to-market strategy - including a pay-as-you-go option and greater focus on pharmacy distribution - is expected to pressure 2026 yea…